Clinical Trial Information

Actinium Pharmaceuticals, Inc. is committed to improving the lives of patients with cancers that lack effective treatment options.

To learn more about Actinium’s current clinical trials please visit the National Institutes of Health registry database of clinical trials that can be found on the following Web page: www.clinicaltrials.gov. Actinium posts information about its clinical trials such as, a description of the study, patient populations and entry criteria and locations where the trial is being conducted. Please click on the links below to learn about our ongoing clinical trials.

Product Candidate Study ID Study Title
Iomab-B NCT02665065 Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA)
Actimab-A NCT02575963 Low Dose Cytarabine and Lintuzumab-Ac225 in Older AML Patients

If you are a patient, health care proxy, or healthcare professional looking for more information about Actinium’s current or future clinical trials, please email requests related to Iomab-B to iomab@actiniumpharma.com  and requests related to Actimab-A to actimab@actiniumpharma.com. An Actinium representative will contact you to provide the requested information.